FIELD: biotechnology.
SUBSTANCE: invention relates to a caninized antibody, including a crystallizable fragment region (cFc region), a hinge region and a combination of complementary determined regions (CDR) of heavy and light chains, as well as to a composition containing it. Also a nucleic acid encoding the heavy chain and the light chain of the above antibody, as well as a vector containing it are provided.
EFFECT: invention is effective for the treatment of PD-1 mediated diseases.
10 cl, 10 dwg, 14 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
ANTI-IL31 ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2835543C1 |
ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2840044C1 |
CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2838943C1 |
IL4 RECEPTOR ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2837141C2 |
ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
PARVOVIRUS ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2830441C2 |
Authors
Dates
2023-08-03—Published
2014-12-19—Filed